Ares Financial Consulting
ANIP icon

Ares Financial Consulting’s ANI Pharmaceuticals ANIP Stock Holding History

Ares Financial Consulting’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$799 Hold
11
– – ﹤0.01% 1003
2026
Q2 		$911 Hold
11
– – ﹤0.01% 1019
2026
Q1 		$836 Hold
11
– – ﹤0.01% 979
2025
Q4 		$868 Buy
+11
New +$952 ﹤0.01% 788

Other funds holding ANIP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Dana Investment Advisors
Dana Investment Advisors Waukesha, Wisconsin $3.69B AUM 30.1% 1-Year Est. Return

Ares Financial Consulting's ANIP Position: Q3 2026 in Review

Ares Financial Consulting held its ANI Pharmaceuticals (ANIP) position steady in Q3 2026 at 11 shares worth $799. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

Ares Financial Consulting first reported a position in ANIP in Q4 2025 and has held it in 4 quarters since. The position peaked at $911 in Q2 2026. 112 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Ares Financial Consulting held 11 shares of ANI Pharmaceuticals worth $799 as of Q3 2026.
  • Ares Financial Consulting left its ANI Pharmaceuticals share count unchanged in Q3 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #1003 holding.
  • Ares Financial Consulting first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Ares Financial Consulting's ANI Pharmaceuticals position peaked at $911 in Q2 2026.
  • 112 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.